Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 27, Issue 3, 2013, Pages 261-267

  Fudin, Jeffrey ^a,e,f,g   Fontenelle, Dania Vanesta ^a,e,f,g   Fudin, Hannah Rebecca ^b   Carlyn, Cynthia ^c   Hinden, Debra Ann ^d   Ashley, Christopher C ^a  

^a STRATTON VA MEDICAL CENTER   (United States)

^b Virtua Memorial   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f UNIVERSITY OF CONNECTICUT   (United States)

^g Landstuhl Regional Medical Center   (United States)

Author keywords

Boceprevir; CYP; Cytochrome P450; Drug interaction; Interaction; Methadone; Morphine; P glycoprotein; PGP; Pharmacokinetic; Telaprevir

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIRECT ACTING ANTIVIRUS AGENT; GLUCURONOSYLTRANSFERASE 2B7; METHADONE; MORPHINE; MORPHINE 6 GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 2B1; TELAPREVIR; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PAIN; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT;

ANALGESICS, OPIOID; ANTIVIRAL AGENTS; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG OVERDOSE; HUMANS; METHADONE; MORPHINE; OLIGOPEPTIDES; P-GLYCOPROTEIN;

EID: 84883680306     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2013.803512     Document Type: Review

References (35)

1. Gatti DC, Cha A. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm. 2012;69:2062-2065.
2. Fudin J, Fontenelle DV, Payne A. Rifampin reduces oral morphine absorption: a case of transdermal buprenorphine selection based on morphine pharmacokinetics. Pain Palliat Care Pharmacother. 2012;26:362-367.
3. Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011;52:812-818.
4. Taylor LE, Swan T. Mayer KH. HIV coinfection with hepatitis c virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55(Suppl 1):S33.
5. Centers for Disease Control and Prevention, Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV/AIDS and viral hepatitis. Available at: http://www.cdc.gov/hepatitis/ Populations/hiv.htm. Accessed February 2, 2012.
6. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48:1387-1395.
7. Hanson D. No methadone therapy for US prisoners. The Fix. May 3, 2011. Available at: http://www.thefix.com/content/nomethadone-therapy-us-prisoners
8. Klevens RM, Hu DJ, Jiles R, et al. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(Suppl 1):S3-S9.
9. Telaprevir. Lexi-Drugs Online. Hudson, OH: Lexi-Comp; 2007. Available at: http://online.lexi.com [subscription required to view]. Accessed January 16, 2013.
10. Center for Disease Control and Prevention. Hepatitis C information for health professionals. September 2002. Available at: http://www.cdc.gov/idu/ hepatitis/hepc and hiv co.pdf. Accessed January 16, 2013.
11. Scimeca HM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mt Sinai J Med. 2000;67:412-422.
12. Jain R, Jain S. Antidepressants in the treatment of chronic pain. Pract Pain Manage. 2011;11(2). Available at: http://www.practicalpainmanagement.com/ treatments/pharmacological/non-opioids/antidepressants-treatment-chronic-pain. Accessed January 16, 2013.
13. Mercer S, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem. 2011;11:1157-1164.
14. Baumann TJ, Strickland JM, Herndon CM. Pain management. In: Talbert RL, DiPiro JT, Matke GR. Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiological Approach. 8th ed. New York: McGraw-Hill; 2011:989-989.
15. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Chabner BA, Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-HIll Professional; 2011:481-526. Available at: http://www.accesspharmacy.com/content. aspx?aID=16663974. Accessed January 16, 2013.
16. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153-1193. (Pubitemid 35398691)
17. Van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigation HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012;52:1574-1583.
18. Virani A, Mailis A, Shapiro LE, Sher NH. Drug interaction in human neuropathic pain pharmacotherapy. Pain. 1997;73:3-13. (Pubitemid 27470820)
19. McPherson ML. Methadone: a complex and challenging analgesic, but its worth it! Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. [Edition if not first.] Bethesda, MD: American Society of Health-System Pharmacists; 2010:107-111.
20. Johnson, J. Methadone. 2005. Available at: http://pubs.acs.org/cen/ coverstory/83/8325/8325methadone.html. Accessed December 31, 2012.
21. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19:13-24.
22. Kristensen K, Christensen CB, Christup LL. The mu1, mu2, delta, kappa opiod receptor binding profiles of methadone stereoisomers and morphine. Life Sci (Life Sciences). 1995;56:45-50.
23. Yang F, Tong X, McCarver DG, Hines RN, Beard DA. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2006;33:485-518. (Pubitemid 43989593)
24. Fonseca F, de la Torre R, D́iaz L, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE 2011;6:e19527. doi: 10.1371/journal.pone.0019527.
25. Bruggermann R J M, Alffenaar JC, Blijlevens N M A. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441-1458.
26. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12:109-124. (Pubitemid 351570866)
27. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478. (Pubitemid 30183327)
28. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol. 2000;58:335-340. (Pubitemid 30497477)
29. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153-1193. (Pubitemid 35398691)
30. Vertex Pharmaceuticals Incorporated. Incivek (telaprevir). Highlights of prescribing information. December 2012. Available at: http://pi.vrtx.com/files/ uspi telaprevir.pdf. Accessed 31 December 2012.
31. Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief. 2012. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm?s cid=mm6126a5 w. Accessed January 31, 2013.
32. Coffman BL, Kearney WR, Green MD, Lowery RG, Tephly TR. Analysis of opioid binding to UDP-gluronosyltranferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy. Mol Pharmacol. 2001;69:1464-1469. (Pubitemid 32510112)
33. Miemi Pasanen MK, Neuvonen PJ. Organic anion transporter polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157-181.
34. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008;20:553-624.
35. Morphine Sulfate (Morphine) [package insert]. Deerfield, IL: Baxter Healthcare Corporation; 2010.